Please login to the form below

Not currently logged in
Email:
Password:

V Bryan Lawlis joins board of KaloBios

Is co-founder of Itero and Covance

KaloBios has announced that Dr V Bryan Lawlis is to join the company's board of directors.

Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

He has entrepreneurial experience, co-founding Itero in 2006 and contract manufacturing firm Covance Biotechnology Services in 1996.

Other previous roles include CEO of Aradigm Corporation, VP of process sciences at Genetech.

His extensive industry knowledge and drug development experience, especially in the manufacturing of therapeutic proteins and antibodies, will serve KaloBios well as we advance the development of our portfolio of proprietary, patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios.

This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

9th August 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics